Name (Synonyms) | Correlation | |
---|---|---|
D003704 | Dementia NIH | 0.50 |
D060825 | Cognitive Dysfunction NIH | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000726 | Dementia HPO | 0.50 |
HP:0001268 | Mental deterioration HPO | 0.32 |
There is one clinical trial.
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices. This test will be developed using innovative technology developed at the Parc Taulí University Hospital, which increases the immunogenicity of SARS-CoV-2 differential antigens. The increased immunogenicity of these antigens will allow to detect, with a high sensitivity and specificity, the antibodies in the serum of patients infected with SARS-CoV-2. This test will serve to confirm dubious results as well as reduce false negatives from the PCR test, which will ultimately help reduce transmission of the infection.
Description: IgG antibodies against COVID-19 RBD
Measure: IgG anti-COVID-19 Time: From May to JulyDescription: IgM antibodies against COVID-19 RBD
Measure: IgM anti-COVID-19 Time: From May to JulyDescription: IgA antibodies against COVID-19 RBD
Measure: IgA anti-COVID-19 Time: From May to JulyDescription: Qualitative result to clasify patients into PCR COVID-19 positive patients and PCR COVID-19 negative patients
Measure: COVID-19 PCR results Time: From May to JulyDescription: The presence or abcense of the typical image of the pneumonia caused by COVID-19
Measure: Radiological studies Time: From May to July